Flanagan’s condensed protocol for neurodegenerative diseases. Implementation in a clinical autopsy setting with partial supervision of a neuropathologist-Reference-Cited by-同舟云学术

Flanagan’s condensed protocol for neurodegenerative diseases. Implementation in a clinical autopsy setting with partial supervision of a neuropathologist

Published:2024-03-12 Issue: Volume: Page:
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

López Aitana,López-Muñoz Samuel,Caballero Gabriela,Castrejon Natalia,Rojo Leonardo,Vidal-Robau Nuria,Muñoz Abel,Ortiz Estrella, ,Archilla Iván,Diaz Sherley M.,Larque Ana Belen,Lopez del Campo Ricardo,Martinez Daniel,Rakislova Natalia,Ramirez Jose,Saez de Gordoa Karmele,Sanfeliu Esther,Rodrigo Maite,García Adriana,Cuatrecasas Miriam,Ribalta Teresa,Aldecoa Iban^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00428-024-03781-0.pdf

Reference41 articles.

1. Nichols E, Steinmetz JD, Vollset SE et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health 7:e105–e125. https://doi.org/10.1016/S2468-2667(21)00249-8

2. Montine TJ, Phelps CH, Beach TG et al (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol 123:1–11. https://doi.org/10.1007/s00401-011-0910-3

3. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800. https://doi.org/10.1212/WNL.58.12.1791

4. Braak H, Alafuzoff I, Arzberger T et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404. https://doi.org/10.1007/s00401-006-0127-z

5. Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486